- Home
- NVS
NVS
Novartis AG
as 02-21-2025 4:00pm EST
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 230.5B | IPO Year: | 1991 |
| Target Price: | $123.67 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 5.87 | EPS Growth: | -17.36 |
| 52 Week Low/High: | $92.35 - $120.92 | Next Earning Date: | 01-31-2025 |
| Revenue: | $51,722,000,000 | Revenue Growth: | 10.85% |
| Revenue Growth (this year): | 3.52% | Revenue Growth (next year): | 2.10% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Novartis AG (NVS): Among the Best Global Stocks to Buy According to Hedge Funds
CNW Group
2 days ago
BMO Expands Canadian Depositary Receipt (CDR) Lineup with 10 New Listings from Europe and Japan
Pharmaceutical Technology
4 days ago
HMRI and Novartis Australia sign MoU to expedite medical research
Zacks
8 days ago
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Insider Monkey
8 days ago
Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to Analysts?
Pharmaceutical Technology
8 days ago
Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia
MT Newswires
9 days ago
Novartis Faces 'Sharp Deceleration' in Growth in Mid-2025, UBS Says
Pharmaceutical Technology
10 days ago
Abcuro secures $200m as it eyes approval for rare muscle disease drug
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.